Test Price
2,800 AED✅ Home Collection Available
CARD11 Gene B-Cell Expansion with NF-κB and T-Cell Anergy Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين CARD11 لتوسع الخلايا البائية مع NF-κB وعدم استجابة الخلايا التائية في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
ملخص تنفيذي: ضمان دقة تشخيصية بنسبة 99.9% عبر مختبر معتمد ISO 9001:2015، مع خدمة سحب عينات منزلية فاخرة ونقل مبرد بطاقم تمريضي مختص، يتضمن استشارة وراثية هاتفية بعد النتيجة. السعر 2800 درهم إماراتي، التواصل عبر واتساب +971545488731 للتحقق من التغطية التأمينية.
- ✓ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Processing.
- ✓ Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection and VIP Mobile Phlebotomy (8 AM–11 PM).
- ✓ Clinical Guidance: Telephonic Post‑Test Clinical Guidance in result interpretation by DHA‑licensed genetic counsellor.
- ✓ Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Clinical Overview
The CARD11 NGS Test sequences the entire CARD11 gene to detect gain‑ or loss‑of‑function variants driving B‑cell expansion, NF‑κB pathway overactivation, and impaired T‑cell anergy. This test is essential for diagnosing primary immunodeficiencies (BENTA disease, CADINS), guiding targeted therapy, and assessing lymphoma risk in patients with unexplained lymphoproliferation or autoimmune features. يكشف التحليل الطفرات المسببة لتوسع الخلايا البائية وخلل الاستجابة المناعية، ويدعم قرارات العلاج المبكر.
| Feature | Our Test (NOVO Genomics) | Closest Alternative (Regional Labs) |
|---|---|---|
| Precision | Full gene coverage (exons + splice sites) with 500x mean depth (99.9% sensitivity) | Partial exon sequencing or limited hotspot panel |
| Methodology | NGS (Next‑Generation Sequencing) + Sanger confirmation | Sanger sequencing only or unspecified NGS with low depth |
| Turnaround Time | 3–4 Weeks | 4–8 Weeks |
| Regulatory Compliance | DHA/MOHAP Licensed, ISO 9001:2015, UAE PDPL | May lack full DHA approval for genetic testing |
Pre‑Test Logistics & Specimen Requirements
Accepted Samples:
- Whole Blood (EDTA tube, 2–5 mL)
- Extracted DNA (≥1 µg, concentration ≥50 ng/µL)
- Dried Blood Spot on FTA Card (one drop, properly air‑dried)
Pre‑Test Instruction:
A detailed clinical history and a genetic counselling session to draw a pedigree chart of family members affected by CARD11‑related disorders are required before sample collection. No fasting or medication discontinuation is necessary, but please inform us of any recent blood transfusions or hematopoietic cell therapy. For minors, legally authorized consent is mandatory under UAE CBD Law 2026.
Physician Insight & Safety Protocol
"As a molecular pathologist, I understand that a genetic finding can be emotionally charged. Variants in CARD11 are highly penetrant, but every result must be integrated with your clinical picture by an immunologist or oncologist. I remind every patient that this test opens a door to proactive management – not a verdict."
— Dr. Prabhakar Reddy, DHA 61713011
Medication Warning
Do not discontinue any prescribed medication without consulting your treating physician. Immunosuppressive or anti‑neoplastic drugs do not interfere with the genetic result but should only be adjusted under specialist supervision.
Safety Exclusion Criteria & Emergency Red Flags
- This test is not suitable for patients who have undergone allogeneic hematopoietic stem cell transplantation within the last 3 months (donor DNA interference).
- Do not use ultra‑low‑volume dried blood spots (< 20 µL) – risk of failed amplification.
- If you experience rapidly enlarging lymph nodes, unexplained fever, severe infection, or neurologic symptoms, seek immediate emergency care – do not wait for the genetic test result.
Patient FAQ & Clinical Guidance
1. ما هو تحليل CARD11 ومتى يُطلب؟
هذا التحليل الجيني الشامل يكشف الطفرات في جين CARD11 المسؤولة عن توسع الخلايا البائية وعدم استجابة الخلايا التائية، ويُستخدم لتشخيص أمراض نقص المناعة الأولية مثل BENTA وCADINS أو تقييم خطورة اللمفوما المبكرة.
This test detects all CARD11 variants linked to B‑cell expansion and T‑cell anergy, providing a definitive diagnosis for primary immunodeficiencies and guiding personalized treatment plans.
2. How accurate is the CARD11 NGS test, and will my insurance cover it?
Our next‑generation sequencing achieves 99.9% diagnostic sensitivity with Sanger confirmation of all reported variants, ensuring no false‑positive or false‑negative calls. Most UAE insurers cover genetic testing when pre‑authorized; our team verifies your coverage directly via WhatsApp before collection.
تبلغ حساسية الاختبار التشخيصية 99.9%، ونقوم بالتحقق من التغطية التأمينية مباشرة قبل السحب.
3. هل يمكن إجراء الفحص لطفلي وما هي شروط الموافقة القانونية؟
نعم، يمكن إجراء الفحص للأطفال على أن يتم تقديم موافقة قانونية موقعة من الوالدين أو الوصي القانوني وفق قانون البيانات الجينية CBD 2026 للقاصرين، ويُرافق ذلك جلسة استشارة وراثية إجبارية.
Yes, children can be tested with legally mandated parental/guardian consent under UAE CBD Law 2026, plus a mandatory pre‑ genetic counselling session to interpret implications for the family.
DHA Licensed Facility: 9834453 | ISO 9001:2015 Cert: INT/EGQ/2509DA/3139
Booking & Insurance Verification: WhatsApp +971 54 548 8731
Support: +971545488731 | 8 AM – 11 PM Daily | UAE PDPL Compliant
* All genetic tests adhere to Federal Decree‑Law No. 41 of 2024, CBD Law 2026, and UAE PDPL.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians